Nuwellis Business Summary

Nuwellis, Inc. (NUWE) is a commercial-stage medical technology company specializing in precision cardiorenal care through its proprietary Aquadex SmartFlow ultrafiltration system. The company operates a high-margin "razor-and-blade" revenue model, generating income from the sale of reusable consoles and recurring revenue from single-use disposable blood circuits and catheters. Nuwellis focuses on treating fluid overload (hypervolemia) in patients unresponsive to medical management, such as diuretics, across three primary clinical segments: pediatric care, cardiac surgery, and hospital-based outpatient settings. Following a strategic pivot in late 2025, the company exited international operations to focus exclusively on the U.S. market, leveraging a nearly four-fold increase in CMS outpatient reimbursement rates to drive growth. Its primary direct competitors include global dialysis and CRRT giants such as Baxter International and Fresenius Medical Care, as well as niche medical equipment peers like IRIDEX and Milestone Scientific; however, Nuwellis differentiates itself by offering a simpler, nursing-led alternative to complex continuous renal replacement therapy (CRRT) that specifically targets isotonic fluid removal without the resource intensity of traditional dialysis. Leadership is spearheaded by President, CEO, and Chairman John L. Erb, a med-tech veteran with over 40 years of experience who previously held executive roles at Johnson & Johnson, Schneider (a Pfizer division), and IntraTherapeutics. Erb returned to lead the company in 2025, bringing stability alongside newly appointed CFO Carisa Schultz (effective February 2026), who previously served as VP of Finance at NeueHealth and held leadership roles at Boston Scientific. The technical roadmap is managed by CTO David Lerner, a serial entrepreneur and co-founder of CorRen Medical with a deep pedigree in medical physics and device innovation. The company’s governance was recently bolstered in January 2026 by the appointments of Katharyn Field (CEO of iSpecimen) and Mika Grasso (Investment Manager at a private family office) to the Board of Directors. Notable institutional backing was reinforced in early 2026 through a $5 million private placement and warrant inducement, providing capital for the strategic acquisition of Rendiatech Ltd. to integrate automated kidney function monitoring into the Aquadex platform.